SEC Tracker
Get the app

Cullinan Therapeutics CGEM

Cullinan Therapeutics reports Q3 2026 financial results

Cullinan Therapeutics (CGEM) filed an 8-K with the SEC on Nov 10, 2026, 7:06 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash and investments of $313.8 million as of September 30, 2026
  2. Runway into 2029
  3. CLN-049 Phase 2 study in R/R AML underway
  4. Zipalertinib NDA submission for first-line EGFR ex20ins NSCLC initiated

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Cullinan Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.